Longjin Pharmaceutical(002750)

Search documents
财达证券晨会纪要-20250520
Caida Securities· 2025-05-20 06:23
Summary of Key Points Group 1: Company Listings - Company 001390 Guqi Fur Materials is set to announce its online subscription rate on May 20, 2025 [1] - Company 301590 Youyou Green Energy will begin its preliminary inquiry on May 20, 2025, with the inquiry period ending on the same day [1] - Company 603049 Zhongce Rubber will also start its preliminary inquiry on May 20, 2025, concluding on the same day [1] Group 2: Trading Suspension Announcements - The Invesco Great Wall S&P Consumer Select ETF (QDII) will be suspended from trading on May 20, 2025, until 10:30 AM to protect investor interests [2] - The Guotai S&P 500 ETF will also be suspended on May 20, 2025, until 10:30 AM for the same reason [2] - Company 000151 Zhongcheng Co., Ltd. is suspended due to plans for issuing shares to acquire assets and raise matching funds, effective from May 16, 2025 [2] - Company 000584 *ST Gongzhi is suspended due to a risk warning regarding potential delisting, effective from April 28, 2025 [2] - Company 000622 *ST Hengli is suspended for failing to disclose periodic reports within the statutory deadline, effective from May 6, 2025 [2] - Company 000627 Tianmao Group is suspended for the same reason as *ST Hengli, effective from May 6, 2025 [2] - Company 000878 Yunnan Copper is suspended due to plans for issuing shares to acquire assets and raise matching funds, effective from May 13, 2025 [2] - Company 002336 *ST Renle is suspended due to a risk warning regarding potential delisting, effective from April 30, 2025 [2] - Company 002708 Guangyang Co., Ltd. is suspended due to plans for issuing shares and cash to acquire assets and raise matching funds, effective from May 19, 2025 [2] - Company 002750 *ST Longjin is suspended due to a risk warning regarding potential delisting, effective from April 25, 2025 [2]
财达证券晨会纪要-20250519
Caida Securities· 2025-05-19 03:04
Summary of Key Points Core Insights - The report highlights the upcoming listings and trading activities of several companies on May 19, 2025, indicating a busy market day with multiple new entries [1][2][3]. Upcoming Listings - Company 001390 Guqi Fur Material will be available for online subscription on May 19, 2025 [1]. - Companies 301595 N Taili and 603014 N Weigao will officially list on the same day, with allocations for general institutional investors [1]. - Company 920060 Wanyuantong will also list on May 19, 2025, specifically for the public portion [1]. Suspension Announcements - Company 002092 ST Zhongtai and 002259 ST Shengda will be suspended for one day due to the announcement of the withdrawal of other risk warnings [2]. - The Invesco Great Wall S&P Consumer Select ETF (QDII) and Guotai S&P 500 ETF will also be suspended until 10:30 AM on May 19, 2025, to protect investor interests [2]. - Company 300506 *ST Mingjia will be suspended for one day following the announcement of the withdrawal of delisting risk warnings [2]. Special Suspensions - Company 000151 Zhongcheng Co. will be suspended due to plans for issuing shares to acquire assets and raise matching funds, effective from May 16, 2025 [3]. - Company 000584 *ST Gongzhi and 000622 *ST Hengli will also face suspensions due to potential delisting risks and failure to disclose periodic reports within the legal timeframe [3]. - Company 002336 *ST Renle will be suspended for one day due to the announcement of potential delisting risks [3].
北交所首例?多公司收到终止上市事先告知书!
Guo Ji Jin Rong Bao· 2025-05-12 10:01
Group 1 - Since May, several companies including *ST Zhongcheng, *ST Renle, *ST Hengli, and *ST Gongzhi have announced receipt of termination of listing advance notice, indicating a trend of companies leaving the capital market [1][3] - As of May 12, 2025, a total of 10 companies have received termination of listing advance notices from the Shanghai and Shenzhen Stock Exchanges, with additional companies like *ST Puli and *ST Xulan also facing similar fates [1][3] - The new delisting regulations have been implemented, leading to the first annual report season under these rules, resulting in multiple companies being warned of delisting risks and several directly delisted [5] Group 2 - *ST Renle reported a net asset of -387 million yuan for 2023 and -404 million yuan for 2024, triggering termination of listing due to financial report issues [3] - *ST Hengli's 2023 net profit was negative, and its revenue was below 100 million yuan, leading to a delisting risk warning [3][4] - *ST Zhongcheng's 2023 net asset was also negative, and its 2024 financial report received a qualified opinion, resulting in a proposed termination of listing [3][4] Group 3 - A total of 9 companies have completed delisting in 2025, with reasons ranging from continuous low stock prices to major violations [6][7] - The companies that have delisted include *ST Meixun, Haitong Securities, and *ST Boxin, among others, with various reasons for their delisting [7][8] - The trend indicates a significant number of companies facing financial difficulties and regulatory challenges, leading to increased scrutiny and potential delisting [10] Group 4 - The Beijing Stock Exchange may see its first delisted company, with Guandao Digital and Yun Chuang Data facing delisting risks due to audit issues [9][10] - Both companies have received audit opinions that could lead to termination of listing if they continue to meet financial delisting criteria in 2025 [10] - A total of 96 companies in the A-share market have been warned of delisting risks due to various financial issues, indicating a broader trend of financial instability among listed companies [10]
多家*ST公司公告,触及退市指标
Huan Qiu Wang· 2025-05-12 02:15
【环球网财经综合报道】日前,有6家*ST公司发布公告称,收到《终止上市事先告知书》,其中5家触及财务类强制退市指标,1家触及交易类强制退市指 标。 具体来看,*ST中程5月7日公告称,公司收到深交所下发的《终止上市事先告知书》,拟被终止股票上市交易。此前,*ST中程因2023年度经审计的期末净 资产为负值,股票交易已被实施退市风险警示。2024年年度报告显示,公司财务会计报告被出具保留意见的审计报告,财务报告内部控制被出具否定意见的 审计报告,触及深交所《股票上市规则(2025年修订)》相关股票终止上市情形。 *ST人乐于5月6日公告称,公司收到《终止上市事先告知书》,深交所拟决定终止其股票上市交易。因2023年度经审计的净资产为负值,公司股票已被实施 退市风险警示。2024年度,公司经审计的期末净资产为-4.04亿元,财务会计报告被出具无法表示意见的审计报告,财务报告内部控制被出具否定意见的审 计报告,触及深交所相关股票终止上市情形。 *ST工智也因2024年度财务会计报告被出具无法表示意见的审计报告,财务报告内部控制被出具否定意见的审计报告,收到《终止上市事先告知书》。公司 5月9日晚公告称,已在规定期限 ...
多重退市风险齐发多家*ST公司收到终止上市事先告知书
Shang Hai Zheng Quan Bao· 2025-05-11 18:27
Core Viewpoint - Multiple *ST companies are facing delisting risks as they have received pre-delisting notices from the exchange due to various financial and trading indicators [2][5][6] Group 1: Financial Indicators and Delisting Notices - As of May 11, six *ST companies have received pre-delisting notices, with five touching financial delisting indicators and one touching trading delisting indicators [2] - The new delisting regulations have introduced stricter conditions for *ST companies to remove delisting risk warnings, requiring internal control audit reports to be unqualified; otherwise, delisting will occur [2][3] - *ST Zhongcheng, *ST Renle, and *ST Gongzhi received negative internal control audit opinions for their 2024 financial reports, indicating significant financial distress [3][5] Group 2: Specific Company Cases - *ST Zhongcheng announced on May 7 that it received a pre-delisting notice due to a negative net asset value for 2023 and a negative internal control audit opinion for 2024 [3][4] - *ST Renle received a pre-delisting notice on May 6, with a reported net asset of -387 million yuan for 2023 and -404 million yuan for 2024, along with negative audit opinions [5] - *ST Gongzhi also received a pre-delisting notice due to negative audit opinions for its financial reports [5] Group 3: Additional Delisting Factors - *ST Longjin is set to exit the A-share market due to negative profit and revenue figures, having received a pre-delisting notice on April 25 [6] - *ST Hengli faced delisting risks for failing to disclose its 2024 annual report on time, with a reported negative net profit and revenue below 100 million yuan [7] - *ST Jiyuan triggered the delisting indicator by having its stock price below 1 yuan for 20 consecutive trading days, leading to a pre-delisting notice [9]
患者输液两小时后离世,专家:中药注射液风控仍有短板
2 1 Shi Ji Jing Ji Bao Dao· 2025-05-09 11:30
Core Viewpoint - The safety concerns surrounding traditional Chinese medicine (TCM) injection solutions, particularly the case of a patient who died after receiving a Schisandra injection, have reignited discussions about the risks associated with these products and the need for improved regulatory oversight [1][3][11]. Industry Overview - The market for TCM injection solutions has seen a significant decline, with total market size dropping from 831.3 billion in 2015 to 479.8 billion in 2023, a nearly 50% reduction [7]. - Major companies in the sector, such as ST Longjin and Dali Pharmaceutical, have faced severe financial difficulties, with ST Longjin's revenue declining by 36.19% to 0.48 billion in 2024 [8][9]. - Despite the challenges, some companies remain optimistic about the potential for TCM injections, with predictions that products like Kanyuan Pharmaceutical's Hot Toxic Ning injection could benefit from increased insurance coverage and expanded indications [5]. Regulatory Environment - The National Medical Products Administration (NMPA) has been actively revising the instructions for TCM injections, adding warnings about severe allergic reactions and requiring monitoring after administration [11][12]. - Recent changes in the 2023 medical insurance drug directory have relaxed some payment restrictions on TCM injections, allowing for broader use in clinical settings [13][14]. - However, the existing risk management system still has shortcomings, such as delayed implementation of revised instructions and insufficient training for medical staff on proper medication use [12]. Safety Concerns - Reports indicate that adverse reactions to TCM injections, particularly allergic reactions, are common, especially among older patients [3][6]. - The complexity of TCM injection formulations and the potential for contamination during production contribute to safety risks [6][10]. - The industry faces ongoing scrutiny regarding the quality control of TCM injections, with calls for stricter regulations and better monitoring of adverse reactions [10][15]. Future Outlook - The TCM injection industry must navigate its way out of the current downturn by focusing on product upgrades, regulatory compliance, and enhancing safety monitoring systems [10][16]. - Companies are encouraged to adopt modern scientific methods to assess the safety of TCM injections and to implement stricter quality control measures [16].
财达证券晨会纪要-20250506
Caida Securities· 2025-05-06 12:31
Summary of Key Points Core Insights - The report highlights various companies undergoing temporary suspensions of trading due to different reasons, including financial disclosures and potential delisting risks. This indicates a volatile market environment where investor confidence may be affected by such events [2][3][4]. Company Specifics - ST Jiuzhi (000989) announced a temporary suspension of trading on May 6, 2025, due to the cancellation of other risk warnings [2]. - In the case of ST Gongzhi (000584), trading was suspended due to a risk warning regarding potential delisting, effective from April 28, 2025 [2]. - ST Hengli (000622) and Tianmao Group (000627) also faced trading suspensions due to their inability to disclose periodic reports within the legal timeframe, effective from May 6, 2025 [2]. - Binhai Energy (000695) is undergoing a trading suspension as it plans to issue shares for asset acquisition and raise matching funds, effective from April 30, 2025 [2]. - Electric Power Investment Energy (002128) is also suspended for similar reasons related to asset acquisition and related party transactions, effective from May 6, 2025 [2]. Industry Context - The report reflects a broader trend in the market where companies are facing increased scrutiny and regulatory challenges, leading to trading suspensions. This could signal potential investment risks in the affected sectors [2][3][4].
*ST龙津(002750) - 关于财务负责人辞职的公告
2025-05-05 07:45
截至本公告披露日,钱熙文先生未持有公司股份,不存在应当履行而未履行 的承诺事项。钱熙文先生在担任公司财务负责人期间恪尽职守、勤勉尽职,公司 董事会对其任职期间为公司做出的贡献表示衷心感谢。 股票代码:002750 股票简称:*ST 龙津 公告编号:2025-048 昆明龙津药业股份有限公司 关于财务负责人辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚 假记载、误导性陈述或重大遗漏。 昆明龙津药业股份有限公司(以下简称"公司")董事会于 2025 年 4 月 30 日收到公司财务负责人钱熙文先生的书面辞职报告,钱熙文先生因个人原因辞任 公司财务负责人,辞职后不再担任公司及子公司任何职务,该辞职报告自送达公 司董事会之日起生效。 为保证公司财务工作的正常开展,在财务负责人空缺期间,暂由公司财务部 部长马榕女士代行职责。公司董事会将按照法定程序,尽快完成新任财务负责人 的聘任。 特此公告。 昆明龙津药业股份有限公司董事会 2025 年 4 月 30 日 1 ...
大结局!上市10年从135元跌到1元,确定退市,里面3万股东被埋!
Sou Hu Cai Jing· 2025-05-01 08:46
Core Viewpoint - ST Longjin is facing delisting due to a net profit loss in the recently disclosed 2024 annual report and revenue falling below 300 million, triggering delisting conditions [2][14]. Company Overview - Longjin Pharmaceutical was established in September 1996, focusing on the research, production, and sales of modern traditional Chinese medicine and high-end chemical generics [2]. - The company’s representative products include injection of Ligusticum Chuanxiong, injection of fibrinolytic enzyme, and injection of Bivalirudin, with Ligusticum Chuanxiong being the core product [2]. Stock Performance - Longjin Pharmaceutical was listed in 2015 during a bull market, with its stock price peaking at 135 yuan before experiencing a significant decline, dropping to around 6 yuan within two years [2]. - In 2019, the company invested 15 million yuan to acquire a 51% stake in Yunnan Muya Agricultural Technology Co., which focuses on large-scale industrial hemp cultivation, leading to a stock price surge from 5 yuan to 23.5 yuan in two months [4]. - The stock was heavily speculated upon due to the industrial hemp concept, achieving multiple trading halts in 2021, earning the title of the "first industrial hemp stock" [4]. Financial Performance - From 2021 to 2024, Longjin Pharmaceutical's revenue showed a drastic decline: 702.5 million, 123 million, 86.62 million, and 66.48 million respectively, with net profits of 3.093 million, -56.12 million, -70.94 million, and -41.44 million, indicating three consecutive years of losses [7]. - The company was placed under delisting risk warning by the Shenzhen Stock Exchange in the previous year due to a negative net profit and revenue below 100 million [8]. Recent Developments - Following the delisting risk warning, Longjin Pharmaceutical's stock faced a series of trading halts, with the price plummeting to around 1 yuan after multiple trading suspensions [9][11]. - Currently, there are nearly 30,000 shareholders, many of whom are stuck with high-priced shares and reluctant to sell [14]. Industry Context - The number of listed companies in A-shares has exceeded 5,000, with an increasing number of delistings each year, highlighting the importance of avoiding poorly performing stocks [16].
*ST龙津(002750.SZ):2025年一季报净利润为-407.99万元
Xin Lang Cai Jing· 2025-05-01 01:53
2025年4月29日,*ST龙津(002750.SZ)发布2025年一季报。 公司截至2025年3月31日,*ST龙津营业总收入为590.18万元,在已披露的同业公司中排名第71,较去年 同报告期营业总收入减少2048.67万元,同比较去年同期下降77.64%。截至2025年3月31日,*ST龙津归 母净利润为-407.99万元,在已披露的同业公司中排名第62。截至2025年3月31日,*ST龙津经营活动现 金净流入为-1284.91万元,在已披露的同业公司中排名第47,较去年同报告期经营活动现金净流入减少 808.48万元。 公司截至2025年3月31日,*ST龙津最新资产负债率为12.60%。 公司截至2025年3月31日,*ST龙津最新毛利率为64.50%,较去年同期毛利率减少4.62个百分点。截至 2025年3月31日,*ST龙津最新ROE为-0.88%,在已披露的同业公司中排名第64。 公司截至2025年3月31日,*ST龙津摊薄每股收益为-0.01元,在已披露的同业公司中排名第61。 公司截至2025年3月31日,*ST龙津最新总资产周转率为0.01次,在已披露的同业公司中排名第71,较去 年同期 ...